drugset / Trial / NCT02834052
Pembrolizumab + Poly-ICLC in MRP Colon Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to determine the dose of poly-ICLC that is safe and tolerable when it is combined with pembrolizumab in patients with colon cancer. This study will also evaluate how the combination of pembrolizumab and poly-ICLC activates the immune system in the patient's blood and inside the tumor; how it affects the size and number of tumor(s) in each patient; and how effective the combination is in patients with colon cancer that is unlikely to respond to pembrolizumab alone.
Timeline
- Start
- 2018-01-10
- Primary completion
- 2022-07-29
- Completion
- 2022-07-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hiltonol | Other / unclassified | 1 mg | Intramuscular |
| Subject | Hiltonol | Other / unclassified | 2 mg | Intramuscular |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |